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Short running title: Phase I/II trial of AT9283 in paediatric leukaemia 
Key words: leukaemia, pediatric, Aurora kinase, AT9283, phase I/II trial 
Abbreviations:  
ABL  Abelson tyrosine kinase 
AE   Adverse event 
ALL Acute lymphoblastic leukaemia 
AML Acute myeloid leukaemia 
AUC0-t Area under the plasma concentration time curve 
BSA Body surface area 
Cmax maximum concentration 
CDD Centre for Drug Development 
Cl clearance 
CNS Central nervous system 
CR-UK Cancer Research UK 
DHPLC Denaturing high performance liquid 
chromatography 
DLT Dose limiting toxicity 
ECG Electrocardiogram 
Echo Echocardiogram 
FBC Full blood count 
FLT3 FMS-like tyrosine kinase 3 
h hour 
JAK Janus kinase 
MLPA Multiplex Ligation-dependent Probe Amplification 
MTD Maximum tolerated dose 
pERK Phosphorylated ERK 
pHH3 Phosphohistone H3 
pSTAT  Phosphorylated Signal Transducer and Activator 
of Transcription 
PCNA Proliferating Cell Nuclear Antigen 
PD pharmacodynamic 
PIA Plasma inhibitory activity 
PK pharmacokinetic 
SAE Serious adverse events 
STAT  Signal Transducer and Activator of Transcription 
Tmax time to reach maximum concentration 
T1/2  elimination half-life 
ULN Upper limit of normal 
Vss steady state volume of distribution 
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Abstract  
Aurora kinases regulate mitosis and are commonly overexpressed in leukaemia. 
This phase I/IIa study of AT9283, a multi-kinase inhibitor, was designed to identify 
maximal tolerated doses, safety, pharmacokinetics and pharmacodynamic activity in 
children with relapsed/refractory acute leukaemia. 
The trial suffered from poor recruitment and terminated early, therefore failing to 
identify its primary endpoints. AT9283 caused tolerable toxicity, but failed to show 
clinical responses. Future trials should be based on robust preclinical data that 
provide an indication of which patients may benefit from the experimental agent, and 
recruitment should be improved through international collaborations and early 
combination with established treatment strategies. 
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Introduction  1 
Leukaemia is the most common malignancy in childhood. Despite treatment 2 
advances, the outcome of relapsed leukaemia remains poor, with 5 year disease-3 
free survival rates for relapsed ALL of 16-39% 1, and relapsed AML of 16-34 % 2. 4 
New treatment strategies are needed to improve survival and reduce toxicity of 5 
conventional chemotherapy. 6 
Aurora kinases are a family of serine/threonine kinases involved in mitosis and 7 
meiosis. The Aurora kinases are overexpressed in many cancers, including 8 
leukaemias 3 and overexpression has been linked to genetic instability.  9 
AT9283 is a multi-kinase inhibitor affecting not only Aurora A and B, but also FMS-10 
like tyrosine kinase 3 (FLT3), the JAK family and ABL 4. All of these are activated in 11 
ALL and AML; FLT3 is commonly activated by mutation and ABL by chromosomal 12 
translocations 5-9. A plethora of early phase clinical trials are evaluating small 13 
molecule inhibitors against these kinases (reviewed in 10,11). Preclinical data have 14 
shown that inhibition of Aurora A, B and FLT3 kinase by compound 27e led to growth 15 
inhibition in a FLT3-ITD-positive AML xenograft 12. AT9283 has shown in vitro activity 16 
in cell line models for myeloproliferative disorders with gain of function mutations in 17 
JAK2 13 and in adult phase I/II trials for solid tumours and haematological 18 
malignancies 14 15. In adult AML, approximately 33% of patients experienced a 19 
reduction in bone marrow blasts 15. The first-in-child phase I trial with AT9283 in solid 20 
tumours lead to a partial response in one patient (diagnosis: CNS-PNET) and 21 
disease stabilisation in 38% of patients, with manageable haematological toxicity 16. 22 
The current study is a first-in-child trial of AT9283 for relapsed/refractory leukaemia. 23 
The aims of the study were to identify the dose for exploration of AT9283 in a phase 24 
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II trial (primary objective), to evaluate safety and tolerability of AT9283 by identifying 25 
dose-limiting toxicities (DLTs), to document preliminary activity and investigate its PK 26 
profile (secondary objectives). Tertiary objectives were to assess target inhibition by 27 
AT9283 with a validated biomarker assay 17 and identify potential predictive 28 
biomarkers. 29 
30 
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Results 31 
Study design, eligibility, dose escalation/drug schedule  32 
Details regarding study design, eligibility criteria, definition of adverse events/dose 33 
limiting toxicities, and information on dose escalation, drug schedule and 34 
assessments are summarised in the Supplemental Appendix S1. Written and signed 35 
informed consent was obtained from all parents/guardians. The trial was sponsored 36 
by Cancer Research UK (CR-UK) Centre for Drug Development (CDD) (study 37 
number CR0708-12, EudraCT number 2009-016952-36, ClinicalTrials.gov identifier: 38 
NCT01431664), and was conducted in accordance with the principles of Good 39 
Clinical Practice and CR-UK CDD’s Standard Operating Procedures. 40 
 41 
Methods 42 
PK analysis was identical to that described previously 16. 43 
The Plasma Inhibitory Activity (PIA) assay was used to measure ex vivo target 44 
kinase inhibition and had been validated for inhibition of Aurora, ABL and FLT3 45 
kinase 17. 46 
Immunohistochemistry was used on surrogate tissue (skin punch biopsies) to assess 47 
in vivo target kinase inhibition of Aurora kinase (change in pHH3 levels), changes in 48 
p53 (accumulation/stabilization) and Ki67/proliferating cell nuclear antigen (PCNA) 49 
levels as biomarkers of anti-proliferative responses 16. 50 
Other PD measurements included: in vivo inhibition of JAK-STAT signalling by flow 51 
cytometry, genetic screen for mutations in JAK1, 2, 3 and FLT3, and copy number 52 
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abnormalities of IKZF1 and PAX5 by Multiplex Ligation-dependent Probe 53 
Amplification (MLPA). Details: see Supplemental Appendix S1. 54 
 55 
Patient characteristics 56 
Ten patients underwent screening, seven of whom were eligible for inclusion into the 57 
trial. Recruitment started in September 2011 and the first patient was treated in April, 58 
2012. Of the 7 patients, 5 (71%) were male, 2 (29%) were female, with a median age 59 
of 3 years (range 1-18 years). Four patients were diagnosed with relapsed/refractory 60 
AML and three patients had relapsed ALL.  61 
Three dose levels of AT9283 were explored: 3 patients each at 9 and 14.5 62 
mg/m2/day, and a further patient at 23 mg/m2/day. Each patient received 1 cycle of 63 
treatment. All patients withdrew from the trial due to disease progression during or at 64 
the end of cycle 1. The trial closed prematurely in July 2014 due to poor patient 65 
recruitment. 66 
 67 
Toxicities 68 
All patients were evaluated for safety. A total of 97 Adverse Events (AEs) were 69 
reported, of which 29 were considered to be related (possible, probable or highly 70 
probable) to the administration of AT9283 (Supplemental Table S1). Five patients 71 
experienced a total of 17 Serious Adverse Events (SAE), of which 13 were 72 
considered to be at least possibly related to AT9283. None of the SAEs observed 73 
were categorised as a DLT (Supplemental Table S2). There was one patient death 74 
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during the trial due to disease progression, 22 days after the last administration of 75 
AT9283. No MTD could be determined in this study. 76 
 77 
Early response signals  78 
None of the patients achieved a complete remission (<5% blasts in bone marrow), a 79 
complete remission with incomplete bone marrow recovery or a partial remission 80 
(<25% blasts in bone marrow).  81 
 82 
Pharmacokinetics and Pharmacodynamic assays 83 
The PK parameters Cmax, AUC, half-life and Cl values were broadly comparable to 84 
the results reported from the paediatric solid tumour study 16. Details on results 85 
regarding pharmacokinetics and pharmacodynamic assays are presented in Figure 1 86 
and 2 (and Supplemental Appendix S1: Results; Supplemental Table S3 and 87 
Supplemental Figure S1).  88 
  89 
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Discussion 90 
The current trial represents a first-in-child study of AT9283 in haematological 91 
malignancies and highlights major challenges encountered when conducting early 92 
phase trials in patients with relapsed leukaemia. Despite being open for almost 3 93 
years, the trial closed prematurely and the primary endpoint of identifying a dose for 94 
phase II exploration was not achieved. AT9283 was well tolerated at the dose levels 95 
explored, without any DLTs, but with expected, mainly haematological toxicity. The 96 
relatively low starting dose of 9 mg/m2/day in comparison with the adult leukaemia 97 
MTD might have contributed towards the fact that no evidence for clinical efficacy 98 
was observed.  99 
Apart from the trial being open at only 4 sites, important reasons for the slow accrual 100 
were the rarity of eligible patients (e.g. patients with second/higher relapse are rare, 101 
CNS disease as exclusion criteria) and competing studies towards the end of the 102 
recruitment period (i.e. Volasertib, Moxetumomab, CAR T-cells, 103 
Dacogen/cytarabine). Furthermore, it demonstrated the challenges in conducting 104 
early phase studies when eligible patients per se are rare and where no pre-105 
selection regarding pathway activation/underlying mutations is undertaken. In our 106 
case, selection for patients with leukaemias carrying JAK, ABL or FLT3 mutations 107 
might have increased the chance of observing clinical responses, which could have 108 
translated into better recruitment. 109 
In summary, the trial showed that AT9283 has tolerable toxicity and confirmed 110 
previous PK data, but it lacked any evidence of efficacy for the doses explored. Our 111 
results, taken together with the experience of AT9283 in adult leukaemia 15, provide 112 
no evidence for AT9283 as an active single agent in leukaemia, and leave only few 113 
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indications like megakaryoblastic leukaemia 18, in which future studies might be 114 
useful. In general, novel agents like AT9283 should be added to established 115 
standard chemotherapy platforms or to upfront single-agent window studies, followed 116 
by other treatment elements, as single agents are unlikely to be the way forward in 117 
these multiply relapsed patients. Furthermore, successful completion of early phase 118 
trials in rare patient populations is difficult in the national setting and such trials are 119 
better conducted within international consortia, in order to maximise patient 120 
recruitment.  121 
 122 
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Legends 192 
 193 
Figure 1: Plot of AT9283 AUC (A) and Cmax (B) versus dose level in the leukaemic 194 
patient population of the study. Despite a high inter-subject variability at both dose 195 
levels studied in 3 patients, there was a general trend towards increased Cmax and 196 
increased exposure to AT9283 (AUC) with increasing dose levels based on BSA 197 
 198 
Figure 2: Plot of Plasma Inhibitory Activity for all patients (A). Phosphorylated 199 
histone H3 raw densitometry data normalised to the corresponding GAPDH signals 200 
on the total blot, expressed as a percentage of the screening sample (set at 100%), 201 
with subsequent measurements at 48 and 96 h. Six out of the seven patients (86%) 202 
had a decrease in pHH3 48 hours after the start of AT9283 infusion, with inhibition of 203 
phosphorylation ranging from 23-87%.   ⃰ p < 0.05 in one-way ANOVA with multiple 204 
comparisons test. Panel 2B shows the relationship between AT9283 concentration 205 
and inhibition of pHH3 phosphorylation at the 48 h time point. 206 
 207 
 208 
  209 
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Legends to supplemental files:  210 
 211 
Supplemental Appendix S1: This section includes details on study design, eligibility 212 
criteria, definition of adverse events/dose limiting toxicities, and information on dose 213 
escalation, drug schedule and assessments. 214 
 215 
Supplemental Table S1: Frequency of Adverse Events (occurring in ≥20% patients) 216 
 217 
Supplemental Table S2: Serious Adverse Events 218 
 219 
Supplemental Table S3: Summary of pharmacokinetic indices 220 
 221 
Supplemental Figure S1: Plot of AT9283 clearance versus body surface area (m2) 222 
for leukaemia patients in the current study (shown in red) and solid tumour patients 223 
(from a previous study, shown in black). 224 
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Supplemental Appendix S1 
Study design  
The trial was an open-label, multi-centre, non-randomized dose-escalation Phase 
I/IIa paediatric study in patients with relapsed (≥2nd relapse) or refractory leukaemia 
(ALL and AML). The trial opened to recruitment at 4 sites across England in 
September, 2011 and closed in July, 2014. The trial was planned to enrol 12-18 
patients in a ‘3+3’ design, with the expectation to enrol 3-5 patients per year, thus 
expecting to remain open for 2.5 years as a minimum. Dose escalation was only 
allowed in the event of ≤1 DLT per cohort.  
 
Patient eligibility  
Patients eligibility criteria included: age >6 months and <19 years, in second (or 
subsequent) relapse of ALL or AML, or patients who were refractory to induction 
treatment in first relapse of ALL or AML, the presence of ≥5 % blasts in the bone 
marrow, a life expectancy of at least 8 weeks, a Karnofsky/Lansky play scale of ≥ 
50%, biochemical indices within specific ranges [serum bilirubin < 1.5x upper limit of 
normal (ULN), Alanine aminotransferase or aspartate aminotransferase <2.5 x ULN, 
creatinine clearance ≥60 ml/min/1.73m2 (Schwartz formula)], signed informed 
consent and being capable of co-operating with treatment and follow-up. 
Exclusion criteria were: a diagnosis of chronic myeloid leukaemia, the presence of 
central nervous system (CNS) disease, cytotoxic chemotherapy within 2 weeks, prior 
exposure to an Aurora kinase inhibitor, ongoing toxicity from previous treatments 
(except alopecia and certain grade 1 toxicities), pregnant/lactating women, 
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participants not agreeing to use highly effective forms of contraception during the 
trial and for 6 months afterwards, major thoracic or abdominal surgery from which 
the patient has not yet recovered, positivity for hepatitis B, C or HIV, decreased 
cardiac function (FS ≤ 29% on Echo), uncontrolled arterial hypertension, congenital 
heart disease, active graft versus host disease or patients with significant toxicity 
following haematopoietic stem cell transplant.  
 
Definition of Adverse Events and Dose Limiting Toxicities 
Adverse events (AE) were classified according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.02. DLTs 
were defined as a probably or highly probably drug-related AE to AT9283 with failure 
to recover an absolute neutrophil count of 0.5 x 109/l and a non-transfusion 
dependent platelet count of 25 x 109/l due to documented bone marrow 
aplasia/hypoplasia by day 42, a >15% reduction in shortening fraction as measured 
by echocardiogram, any AE with fatal outcome, and any grade 3 or grade 4 non-
haematological toxicity (but excluding: alopecia, reversible grade 3 nausea/vomiting, 
within 48 hours resolving grade 3 mucositis, within 14 days resolving grade 3 
transaminitis, and grade 3 fever with neutropenia).  
Dose escalation, drug schedule and assessments 
The starting dose of AT9283 was 9 mg/m2/day for 3 days, which is less than 10% of 
the adult maximum tolerated dose (MTD, 108 mg/m2/day) in a phase I trial with 
haematological patients [1]. This conservative approach was chosen as significant 
fatal cardiac toxicity had been observed at the dose level above the MTD in the adult 
haematological study and also as the MTD in the adult solid tumour study had been 
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determined as 9 mg/m2/day [2]. The MTD in the paediatric solid tumour trial of 
AT9283 was found to be 18.5 mg/m2/day, but that was not known at the time point of 
first patient enrolment, as the two trials were conducted partially overlapping. A 
further dose escalation to 12 mg/m2/day was planned, but later revised to 14.5 
mg/m2/day, after review of the safety and PK/PD data of the paediatric solid tumour 
study (MTD 18.5 mg/m2/day) [3]. A further dose escalation of up to 100% greater 
than 14.5 mg/m2/day was subsequently allowed. 
AT9283 was supplied by Astex Therapeutics Ltd; and reconstituted, diluted and 
given i.v. over 72 hours on days 1-3 of a 21 day cycle as previously described [3]. 
Treatment was planned to continue for up to 6 cycles, and patients had to have at 
least a partial remission (PR) after cycle 1 to continue with the next cycle. 
At screening, physical examination including vital signs, performance status, height, 
weight and body surface area (BSA) were obtained, and full blood count (FBC), 
biochemistry, urinalysis, pregnancy test, chest X-ray, Echo and ECG were 
performed. Patients had a diagnostic lumbar puncture to exclude CNS disease and a 
bone marrow aspirate and optional trephine for disease assessment. A skin punch 
biopsy was taken at baseline and at the end of the first 72 hour infusion for in vivo 
PD assessments. During the study period, patients were reviewed with physical 
examination, vital signs, assessment of AE and twice weekly haematology and 
weekly biochemistry laboratory tests. A bone marrow aspirate and trephine was 
obtained upon recovery of counts to assess disease status. Before a second cycle, 
Karnofsky/Lansky performance status, BSA, vital signs, height/weight, vital signs, 
laboratory tests (haematology and biochemistry), Echo and assessment of AE were 
repeated. At the off-study visit, and in addition to the above assessments, a bone 
marrow aspirate was repeated if none had been performed during the previous 4 
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weeks, and could be omitted if rising blast cell counts in peripheral blood signified 
disease progression.  
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Methods 
Pharmacodynamic studies 
Leukaemic patients often have blasts in their peripheral blood which are amenable 
for biomarker and pharmacodynamics studies. Blood samples were taken at 
screening and 4, 48 and 96 hours after the start of infusion on cycle 1. A skin punch 
biopsy was taken at baseline and at 72 hours (+/- 2 hours) following the start of the 
drug infusion on cycle 1. 
Plasma Inhibitory Activity (PIA) assay 
Aurora kinase and FLT3 kinase act by phosphorylating histone H3 (HH3) and 
activating the RAS/RAF/MEK/ERK pathway, respectively, thus levels of pHH3 and 
pERK1/2 can serve as biomarkers of their kinase activity. The PIA assay involved 
the incubation of a FLT3-ITD positive AML cell line (MOLM-13) with plasma from 
patients treated with AT9283 as previously described [4]. Total Histone H3 and 
ERK1/2 were blotted to confirm modulation of the phosphorylated proteins were not 
due to changes in total protein levels. Quality controls consisted of human male 
plasma (SeraLab) spiked with high, medium and low concentrations of AT9283. 
Positive and negative controls for pHH3 consisted of specimens of human breast 
carcinoma with known antigenic reactivity. 
Other pharmacodynamics assays 
Assessment of the in vivo inhibition of the JAK-STAT pathway by AT9283 was 
performed for patients with white cell counts of >10x109/l. Phosphorylated STAT5 
was measured in leukaemic blasts at baseline and 4 hours post start of AT9283 
infusion by flow cytometry using an anti-STAT5 (Tyr 694) antibody (BD Biosciences). 
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The mean fluorescent intensities of baseline isotype antibody staining compared to 
pSTAT5 antibody staining, relative to the ratios after 4 hours AT9283 infusion time, 
were evaluated. 
Genetic analyses were performed for mutations in hot spot regions of JAK1, 2, 3 and 
FLT3 by denaturing high performance liquid chromatography (DHPLC) as previously 
described [5, 6]. For copy number abnormalities in IKZF1 and PAX5, Multiplex 
Ligation-dependent Probe Amplification (MLPA) was performed using the SALSA 
MLPA kit IKZF1 P335 (MRC Holland, Amsterdam, the Netherlands) [7].  
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Results 
Pharmacokinetics 
Blood samples for PK measurements were obtained from all 7 patients. In 54% of 
patients (4/7), plasma concentrations of AT9283 increased to achieve steady-state 
concentrations within the first 24 hours after the start of infusion. In 3 patients (43%) 
the plasma concentration of AT9283 continued to rise after 24 hours and peaked at 
72 hours. All AT9283 plasma PK parameters are summarized in Table III. Cmax, 
AUC, half-life and Cl values were broadly comparable to the results reported from 
the paediatric solid tumour study. 
Despite a high inter-subject variability at both dose levels studied in 3 patients, there 
was a general trend towards increased Cmax and increased exposure to AT9283 
(AUC) with increasing dose levels based on BSA (see Fig 1, main text). Clearance of 
AT9283 (uncorrected for SA) plotted against body size suggested a trend towards 
increased clearance of AT9283 with larger body surface area. However, this 
correlation was less clear when comparable data from the paediatric solid tumour 
trial of AT9283 were included in the analysis (Fig 3, supplementary material below).  
 
Pharmacodynamic biomarkers 
Plasma Inhibitory Activity assay 
All seven patients had blood samples taken pre-treatment and at 48 and 96 hours 
post start of infusion for ex vivo PIA analysis. Six out of the seven patients (86%) had 
a decrease in pHH3 at serine 10 residue 48 hours after the start of AT9283 infusion, 
with inhibition of phosphorylation ranging from 23-87%. A dose of 14.5 mg/m2/day 
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was required to achieve statistically significant ex vivo inhibition of pHH3. The patient 
who showed no inhibition of pHH3 at 48 hours was treated in the first cohort (9 
mg/m2/day dosing) and showed an inhibition of 33% at the 96 hour time point. 
Overall, the results of the PIA assay for pHH3 correlate with the dose of AT9283, 
with the least inhibition in cohort 1 (9 mg/m2/day dosing) and the greatest inhibition 
being observed in the cohort 3 patient (23 mg/m2/day), who achieved 87% inhibition 
at 48 hours but returned to above pre-screening levels at 96 hours (239%). 
Combining the data for all patients analysed, the inhibition of pHH3 after 48 hours of 
AT9283 treatment was statistically significant (p<0.05) by one-way ANOVA analysis 
with multiple comparisons (Fig 2A). Figure 2B shows the relationship between 
AT9283 concentration at 48 h and inhibition of pHH3 phosphorylation at the same 
time point. The r value of 0.82 suggests a clear relationship between the two 
parameters, albeit with a small number of patients (n=6, as a plasma sample from 
one patient was missing).  
 
Immunohistochemistry 
Skin punch biopsies obtained pre-treatment and at 72 hours after the start of drug 
infusion were used to measure in vivo inhibition of Aurora kinase (change in pHH3 
levels), possible changes in p53 (accumulation/stabilisation) and anti-proliferative 
responses (Ki67/ PCNA levels). Six out of seven patients were evaluable for PD 
analysis, as one patient had not had a 72 hour post-treatment biopsy taken. There 
was no consistent result for pHH3 staining or quantification of pHH3 staining as 
expressed by a histoscore (ranging from 0-300), with 3/6 patients (50%) showing an 
increase in the histoscore post treatment, 2/6 patients (33%) demonstrating 
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stabilisation (no change), and the remaining patient with minimal scores pre- and 
post-treatment. Therefore, in vivo target inhibition of AT9283 in the form of a 
reduction in pHH3 could not be confirmed in the present study. Equally, p53 levels 
were consistently reduced in all patients of cohorts 1 and 2, therefore p53 could not 
be confirmed as a biomarker of target kinase inhibition. Only 1/6 patients (cohort 3) 
showed a slight accumulation of p53 after AT9283 treatment. Ki-67 staining and 
PCNA levels were variable and not consistent in the subjects analysed. 
 
In vivo inhibition of JAK-STAT pathway 
Due to low peripheral white cell counts, only three patients with white cell counts 
>10x109/l were eligible for assessment of pSTAT5 by phosphoflow and blood 
samples were obtained from only two of these patients. Both patients showed mean 
fluorescent intensities at baseline comparable to the negative control cell line and 
thus neither patient was shown to have constitutive activation of the JAK-STAT 
pathway. This finding was consistent with the absence of JAK1, JAK2 or JAK3 
mutations in the bone marrow of both patients. 
 
Genetic analyses 
Genomic DNA from bone marrow samples from all 7 patients was screened for 
mutations in key exons in FLT3, JAK1, JAK2 and JAK3. In total, 10 PCR amplicons 
scored aberrant by DHPLC and were sequenced, revealing 9 single nucleotide 
polymorphisms and 1 activating JAK2 mutation (R683S), which was verified by 
Sanger sequencing. This mutation has been shown in experimental models to be 
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oncogenic and confers sensitivity to JAK inhibitors [8]. Unfortunately, this patient who 
had ALL was not one of the two tested for activated JAK-STAT pathway by flow 
cytometry due to low peripheral white blood cell counts. MLPA analyses for PAX5 
and IKZF1 were performed in 2 of 3 ALL patients. One showed a deletion in IKZF1 
(exon 2-7). Copy numbers for PAX5 for both patients were normal.  
 
Legend to supportive Figure 3: 
Plot of AT9283 clearance versus body surface area (m2) for leukaemia patients in 
the current study (shown in red) and solid tumour patients (from a previous study, 
shown in black). 
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Supplemental TABLE S1 Frequency of Adverse Events (occurring in ≥20% 
patients) 
 
AE body system Number of episodes (number of patients, % [n=7]) 
AE  All AEs  
Grades 1-5 
Related AEs 
Grades 1-5 
Related AEs 
Grades 3-5 
Blood & lymphatic disorders 
Anaemia 
Febrile neutropenia 
14 (6, 85.7%) 
7 (4, 57.1%) 
4 (3, 42.9%) 
6 (4, 57.1%) 
2 (1, 14.3%) 
4 (3, 42.9%) 
6 (4, 57.1%) 
2 (1, 14.3%) 
4 (3, 42.9%) 
Gastrointestinal disorders 
Nausea 
vomiting 
15 (5, 71.4%) 
2 (2, 28.6%) 
6 (4, 57.1%) 
3 (1, 14.3%) 
1 (1, 14.3%) 
2 (1, 14.3%) 
1 (1, 14.3%) 
1 (1, 14.3%) 
- 
Investigations 
Neutrophil count decreased 
Platelet count decreased 
White blood cell decreased 
21 (6, 85.7%) 
3 (3, 42.9%) 
5 (4, 57.1%) 
4 (3, 42.9%) 
10 (5, 71.4%) 
2 (2, 28.6%) 
2 (2, 28.6%) 
3 (3, 42.9%) 
7 (4, 54.1%) 
2 (2, 28.6%) 
1 (1, 14.3%) 
3 (3, 42.9%) 
Metabolism & nutrition 
disorders 
Hypophosphatemia 
Hypokalemia 
12 (4, 57.1%) 
 
4 (2, 28.6%) 
2 (2, 28.6%) 
4 (2, 28.6%) 
 
2 (1, 14.3%) 
1 (1, 14.3%) 
1 (1, 14.3%) 
 
- 
1 (1, 14.3%) 
 
AE: Adverse Event 
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Supplemental TABLE S2 Serious Adverse Events 
 
Body System Total number of 
SAEs 
Total number of 
related SAEs 
Number of 
patients 
% (N=7) 
All SAEs  17 13 5 71.4 
Blood & lymphatic disorders 
Febrile neutropenia 
Other – increase in white cell 
count 
 
4 
1 
 
4 
1 
 
3 
1 
 
42.9 
14.3 
Cardiac disorders 
Sinus tachycardia 
 
1 
 
1 
 
1 
 
14.3 
Gastrointestinal disorders 
Nausea 
Vomiting 
 
1 
2 
 
1 
2 
 
1 
1 
 
14.3 
14.3 
General disorders and 
administration site conditions 
Death 
Pain 
 
 
1 
1 
 
 
- 
- 
 
 
1 
1 
 
 
14.3 
14.3 
Infections and Infestations 
Sepsis 
 
2 
 
2 
 
1 
 
14.3 
Investigations 
Neutrophil count decreased 
 
1 
 
1 
 
1 
 
14.3 
Musculoskeletal and 
connective tissue disorders 
Bone Pain 
 
 
1 
 
 
- 
 
 
1 
 
 
14.3 
Vascular disorders 
Hypotension 
 
2 
 
2 
 
1 
 
14.3 
 
SAE: Serious Adverse Event 
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Supplemental TABLE S3 Summary of pharmacokinetic indices 
 
Patient Nr Dose level 
(mg/m
2
/day) 
Cmax (ng/ml) AUC 
(ng/ml.h) 
Half-life (h) Cl (l/h) Vss (l) 
1 9 40.9 1443 5.1 12.7 91.9 
2 9 8.7 432 4.5 26.1 164.7 
3 9 16.0 1096 6.2 38.3 335.2 
Mean  ± SD 9 21.9  ±16.9 990 ± 514 5.3  ± 0.9 25.7 ± 12.8 197 ± 125 
4 14.5 46.8 3256 6.1 6.3 54.6 
5 14.5 40.9 2137 4.1 10.0 57.3 
6 14.5 24.8 1412 5.7 53.1 427.9 
Mean  ± SD 14.5 37.5  ± 11.4 2268 ± 929 5.3 ± 1.1 23.1 ± 26.0 180 ± 215 
7 23 46.0 2766 5.3 18.4 141.7 
 
Cmax: maximum concentration 
AUC: Area under the plasma concentration time curve 
Cl: clearance 
Vss: steady state volume of distribution 
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